In the News

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

Experience the words and artwork of three patients who found hope and healing through MSK art programs.

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

A team from MSK is undertaking new research to study the genes found on the Y chromosome and their role in cancer.

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.

Learn how to get enough calories during treatment from MSK specialists in diet and nutrition.

One size does not fit all when it comes to treating renal cell carcinoma.

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

Genetic sequencing of prostate tumors can identify men who should receive immunotherapy drugs.

The scientific world lost one of its greats this week. Here, we reflect on his influence.